ArticleBioFactors (Oxford, England)
Trihydroxylated Anthocyanins Potentiate Effects of Docetaxel in Mesenchymal Triple Negative Breast Cancer Cells.
Article in BioFactors (Oxford, England). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Adjuvant therapies by anthocyanins potentially mitigating drug resistance and metastatic disease risks in stratified breast cancers: the 3PM-conceptual innovation targeted to NF-kappaB/EMT plasticity.The EPMA journal · 2026Article
- Trihydroxylated Anthocyanins Potentiate Effects of Docetaxel in Mesenchymal Triple Negative Breast Cancer Cells.BioFactors (Oxford, England)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Triple negative breast cancer (TNBC) presents a significant therapeutic challenge due to its poor prognosis and limited treatment options. While anthocyanins, a group of flavonoids, exhibit promising anticancer potential, their structure-activity relationship and adjuvant properties in TNBC remain underexplored. This study evaluated the anti-proliferative effects of five structurally distinct anthocyani(di)ns-cyanidin-3-O-glucoside (C3G), delphinidin-3-O-glucoside (D3G), delphinidin-3-O-rutinoside (D3R), malvidin-3-O-glucoside (M3G), and luteolinidin (LT)-on mesenchymal TNBC cells. Combination assays of docetaxel (DT), a first-line chemotherapeutic agent, with the most potent anthocyani(di)ns were conducted with TNBC and MCF-12A non-cancerous cells. Trihydroxylated anthocyanins (D3G and D3R), particularly those with a monosaccharide at C3, demonstrated the strongest anti-proliferative effects, reducing MDA-MB-231 cell proliferation by 95% and 70%, respectively, at 400 μM (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.